In this 2-part series, the National Eczema Association outlines its comprehensive State of AD Indicator Report, providing a foundation for targeted action nationwide.
In this 2-part series, the National Eczema Association outlines its comprehensive State of AD Indicator Report, providing a foundation for targeted action nationwide.
New research will explore key aspects of eczema, from the science and genetics behind inflammation to advanced screening and patient-reported outcomes.
New research will explore key aspects of eczema, from the science and genetics behind inflammation to advanced screening and patient-reported outcomes.
The National Eczema Association offers practical guidance on assessing transition readiness and empowering adolescents and young adults as they move toward independent atopic dermatitis care.
The National Eczema Association offers practical guidance on assessing transition readiness and empowering adolescents and young adults as they move toward independent atopic dermatitis care.
As eczema care continues to progress toward different treat-to-target and other shared treatment goals with patients, self-monitoring can be integral to support this evolving care framework.
As eczema care continues to progress toward different treat-to-target and other shared treatment goals with patients, self-monitoring can be integral to support this evolving care framework.
National Eczema Association researchers offer practical guidance grounded in real-world patient and provider needs to optimize long-term atopic dermatitis control and better support patient self-management.
National Eczema Association researchers offer practical guidance grounded in real-world patient and provider needs to optimize long-term atopic dermatitis control and better support patient self-management.
The All of Us database highlights the complexity of eczema beyond atopic dermatitis and emphasizes the need for a more nuanced approach in both clinical practice and research.
The All of Us database highlights the complexity of eczema beyond atopic dermatitis and emphasizes the need for a more nuanced approach in both clinical practice and research.
National Eczema Association survey examines the frequency of acute care needs among patients with atopic dermatitis and the wait times they experience when seeking care from their primary atopic dermatitis health care providers.
National Eczema Association survey examines the frequency of acute care needs among patients with atopic dermatitis and the wait times they experience when seeking care from their primary atopic dermatitis health care providers.
New research will explore key aspects of eczema, from the science and genetics behind inflammation to advanced screening and patient-reported outcomes.
New research will explore key aspects of eczema, from the science and genetics behind inflammation to advanced screening and patient-reported outcomes.
Dr Hilary Baldwin discusses how evolving insights into the skin microbiome are reshaping the understanding of acne, eczema, rosacea, and other inflammatory skin diseases.
Dr Hilary Baldwin discusses how evolving insights into the skin microbiome are reshaping the understanding of acne, eczema, rosacea, and other inflammatory skin diseases.
Dr Hilary Baldwin discusses how evolving insights into the skin microbiome are reshaping the understanding of acne, eczema, rosacea, and other inflammatory skin diseases.
Dr Hilary Baldwin discusses how evolving insights into the skin microbiome are reshaping the understanding of acne, eczema, rosacea, and other inflammatory skin diseases.
The National Eczema Association offers practical guidance on assessing transition readiness and empowering adolescents and young adults as they move toward independent atopic dermatitis care.
The National Eczema Association offers practical guidance on assessing transition readiness and empowering adolescents and young adults as they move toward independent atopic dermatitis care.
A clinical update on chronic hand eczema, highlighting delgocitinib cream, ruxolitinib, gusacitinib, dupilumab, tralokinumab, and biomarker-driven Th1/Th2/Th17 endotypes.
A clinical update on chronic hand eczema, highlighting delgocitinib cream, ruxolitinib, gusacitinib, dupilumab, tralokinumab, and biomarker-driven Th1/Th2/Th17 endotypes.
As eczema care continues to progress toward different treat-to-target and other shared treatment goals with patients, self-monitoring can be integral to support this evolving care framework.
As eczema care continues to progress toward different treat-to-target and other shared treatment goals with patients, self-monitoring can be integral to support this evolving care framework.
The session emphasized mechanism-driven selection, real-world application, and a comparison of pivotal efficacy data for the 3 IL-13–related biologics currently available: dupilumab, lebrikizumab, and tralokinumab.
The session emphasized mechanism-driven selection, real-world application, and a comparison of pivotal efficacy data for the 3 IL-13–related biologics currently available: dupilumab, lebrikizumab, and tralokinumab.
The session focused on elevating therapeutic expectations in AD care, analyzing data on existing JAK inhibitors, and encouraging dermatologists to challenge treatment inertia.
The session focused on elevating therapeutic expectations in AD care, analyzing data on existing JAK inhibitors, and encouraging dermatologists to challenge treatment inertia.
